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Abstract
Objectives: To investigate the relationships between interferon alpha (IFNα) and the clinical and serological
phenotype of patients with systemic autoimmune rheumatic disease (SARDs) in order to determine whether a
distinct subpopulation of patients can be identified.
Methods: We recruited patients with at least 1 SARD clinical feature and at least 1 SARD-related autoantibody from
two NHS Trusts in Greater Manchester. A 6-gene interferon-stimulated gene (ISG) score was calculated in all
patients, and in a subgroup, a 30-gene ISG score was produced using NanoString. A digital Single Molecule Array
(Simoa) was used to measure plasma IFNα protein. In an exploratory analysis, whole blood RNA sequencing was
conducted in 12 patients followed by RT-qPCR confirmation of expression of 6 nucleic acid receptors (NARs) in the
whole cohort.
Results: Sixty three of 164 (38%) patients had a positive ISG score. The 3 measures of IFNα all correlated strongly
with each other (p < 0.0001). There were no differences in mucocutaneous or internal organ involvement between
the ISG subgroups. The ISG-positive group had increased frequency of specific autoantibodies and haematological
abnormalities which remained significant after adjusting for the SARD subtype. Expression of DDX58, MB21D1 and
TLR7 was correlated with the ISG score whilst TLR3, TLR9 and MB21D1 were associated with neutrophil count.
Conclusion: In SARD patients, IFNα-positivity was associated with specific autoantibodies and haematological
parameters but not with other clinical features. The variable NAR expression suggests that different pathways may
drive IFNα production in individual patients. The identification of an IFNα-positive subgroup within a mixed SARD
cohort supports a pathology-based approach to treatment.
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Introduction
Systemic Autoimmune Rheumatic Diseases (SARDs) are a
group of multisystem autoimmune disorders with overlap-
ping clinical and serological manifestations. Patients may
transition between clinical disease categories over time;
some evolve from an undifferentiated connective tissue
disease (UCTD) to a specific disease type, whilst others
develop an overlap syndrome. The significant commonal-
ity in clinical features and autoantibody profiles between
some conditions suggests a shared molecular aetiology,
whilst within a single-disease group significant molecular
heterogeneity has been described [1]. Studies seeking to
understand disease pathogenesis, identify reliable bio-
markers, or develop novel treatment strategies may there-
fore be improved if undertaken in a molecularly defined
subgroup of SARD patients, rather than in traditionally
classified individual conditions [2]. The molecular tax-
onomy of SARDs offers new opportunities in clinical trial
design; therefore, it is essential to better understand
whether true immunopathological subsets of patients ex-
ists within clinical SARD cohorts.
Previous single-disease studies have demonstrated an
increase in type I interferon (IFN) in some SARDs (not-
ably Systemic Lupus Erythematosus (SLE) and Sjogren’s
syndrome (SS)) [3–5]. However, it is less clear whether
those SARD patients expressing a high level of IFNα
represent a homogenous molecular subgroup.
The type I IFNs are a family of 17 cytokines compromis-
ing predominantly of IFNα subtypes. Thirteen IFNα sub-
types have been identified in humans, with the coding
genes all located on chromosome 9 [6]. Studies to date
have been challenging due to the relatively low abundance
of IFNα in the circulation, and the lack of adequately spe-
cific antibodies to confidently distinguish between the
IFNα subtypes and between IFNα and other type I and
type III IFNs (IFNλ). The ‘gold standard’ has therefore
been the measurement of interferon-stimulated genes
(ISGs) either directly in human samples or via an ex vivo
stimulation assay [7, 8]. More recently, a highly sensitive
digital ELISA has been trialled in adult and paediatric pa-
tients with SLE and juvenile dermatomyositis [9, 10].
We aimed to investigate type I IFN pathway activity
using multiple methodologies in an unselected adult
SARD cohort and to determine how this related to the
clinical and immunological phenotype of patients. We
also used unbiased transcriptome analysis of a subgroup
of patients and investigated relevant IFN pathway mole-
cules in order to move beyond classical physician diag-
noses and towards a molecular taxonomy of SARDs.
Methods
Patients and healthy volunteers
Patients were recruited into the Lupus Extended Auto-
immune Phenotype (LEAP) cohort from Manchester
University NHS Foundation Trust (3 sites) and Salford
Royal NHS Foundation Trust (1 site). The LEAP cohort
includes patients with SLE, SS, UCTD, mixed connective
tissue disease (MCTD), systemic sclerosis (SSc) and idio-
pathic inflammatory myopathies (IIM). Ethical approval
was obtained from the Greater Manchester East Re-
search Ethics Committee (13/NW/0564), and the study
was conducted in accordance with the Declaration of
Helsinki. Patients with an established diagnosis and clin-
ically stable disease were eligible for inclusion if they
had ≥ 1 clinical feature of a connective tissue disease and
≥ 1 relevant autoantibody. Autoantibodies were mea-
sured according to physician discretion but all included
the BioPlex 2200 ANA Screen with MDSS (comprising
the following autoantigens: dsDNA, Chromatin/nucelo-
some, Ro/SS-A, La/SS-B, Smith [Sm], SmRNP, RNP, Scl-
70, Jo-1 and centromere). The physician (rheumatolo-
gist) diagnosis was used as the primary classifier of pa-
tients. Detailed clinical and serological data were
recorded. Whole blood was collected for subsequent
RNA analysis. Routine clinical biochemical and haem-
atological parameters were measured, and additional
plasma samples were collected for IFNα protein meas-
urement (see below).
Healthy volunteers were recruited to provide compara-
tor cohorts. For measurement of the ISG score, 29
healthy controls (16/29, 55% female), with a median age
24 years, were recruited (this cohort has been as previ-
ously described [11]). For the NanoString analysis, 27 of
the 29 volunteers above were sampled: 16/27 (59%) fe-
male, median age 34 years. For the nucleic acid receptors
analysis, 16 healthy controls (14/16 (88%) female) with a
median age of 42 years were used.
ISGs
Blood was collected into PAXgene tubes (PreAnalytix)
kept at room temperature for between 2 and 72 h, frozen
at − 20 °C, then stored at − 80 °C until extraction. Total
RNA was extracted from whole blood using a PAXgene
(PreAnalytix) RNA isolation kit. RNA concentration was
assessed by Qubit 2.0 fluorometer (Thermo Fisher Sci-
entific). After DNAse treatment, RNA was converted
into cDNA with the high-capacity cDNA reverse tran-
scriptase kit (Qiagen). Quantitative reverse transcription
polymerase chain reaction (RT-qPCR) analysis was per-
formed using the TaqMan Universal PCR Master Mix
(Applied Biosystems), and cDNA derived from 40 ng
total RNA. Using TaqMan probes for IFI27
(Hs01086370_m1), IFI44L (Hs00199115_m1), IFIT1
(Hs00356631_g1), ISG15 (Hs00192713_m1), RSAD2
(Hs01057264_m1) and SIGLEC1 (Hs00988063_m1), the
relative abundance of each target transcript was normal-
ised to the expression level of HPRT1 (Hs03929096_g1)
and 18S (Hs999999001_s1) and assessed with the
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Applied Biosystems StepOne Software v2.1 and Data As-
sist Software v.3.01. For each of the six probes, individ-
ual (patient and control) data were expressed relative to
a single calibrator. The median fold change of the six
ISGs, when compared to the median of the combined
data of healthy controls, was used to create an interferon
score for each patient as previously described [11]. RQ is
equal to 2−ΔΔCt, i.e. the normalised fold change relative
to a control. The mean interferon score of the healthy
controls plus two standard deviations above the mean
(+ 2SD) was calculated. Scores above this value (> 2·466)
were designated as positive.
Nucleic acid receptors (NARs)
RNA was extracted from whole blood, and RT-qPCR
analysis was performed as described above using 18S
and HPRT1 as reference probes. TaqMan probes for
DDX58 (Hs01061436_m1), MB21D1 (Hs00403553_m1),
TMEM173 (Hs00736956_m1), TLR3 (Hs01551079_g1),
TLR7 (Hs01933259_s1) and TLR9 (Hs00370913_s1)
were used. For each of the six probes, individual (patient
and control) data were expressed relative to a single
calibrator.
Quantification of interferon alpha (IFNα) protein levels in
plasma using a single molecule array (Simoa)
As described by Rodero et al., the Simoa IFNα assay was
developed using a Quanterix Homebrew Simoa assay ac-
cording to the manufacturer’s instructions and utilising
two autoantibodies specific for IFNα isolated and cloned
from 2 APS1/APECED patients [9, 12]. The 8H1 antibody
clone was used as a capture antibody after coating on
paramagnetic beads (0.3mg/mL), and the 12H5 was bio-
tinylated (biotin/Ab ratio = 30/1) and used as the detector.
Recombinant IFNα17/αI (PBL Assay Science) was used as
a standard curve after cross-reactivity testing. The limits
of detection (LOD) were calculated by the mean value of
all blank runs + 3SDs and was 0.23 fg/ml.
NanoString ISG analysis
Gene expression of 30 interferon-stimulated genes and 3
housekeeping genes (HPRT1, NRDC, OTUD5, for de-
tails see Additional file 1) was measured. A 30 gene
score was calculated based on the same methods for the
RT-qPCR score (+ 2SD of healthy controls). Scores
above 1.642 were considered positive. All ISG, NAR and
NanoString measurements were conducted on single
RNA samples.
Gene expression analysis by RNA sequencing (RNA-Seq)
Whole transcriptome expression analysis was performed
using samples from 12 participants, selected according to
the ISG score and presence/absence of anti-Smith anti-
bodies (see Additional file 1: Supplementary methods for
details). Gene lists were uploaded into Ingenuity Pathway
Analysis (http://www.ingenuity.com) in order to deter-
mine differentially regulated canonical pathways in the pa-
tients. ISGs were identified within the RNA-Seq dataset by
comparing differentially expressed genes with the Interfer-
ome v2.0 database [13] (accessed from http://www.inter-
ferome.org/interferome/home.jspx on 8/6/2018).
Availability of data
The RNA-Seq dataset supporting the conclusions of this
article is available in the Array Express repository, (E-
MTAB-7080, https://www.ebi.ac.uk/arrayexpress/experi-
ments/E-MTAB-7080).
Statistical analysis
Statistics were calculated using STATA v.13 (STATcorp,
USA), GraphPad Prism version 5.0d for Mac OS X and
version 7.00 for Windows (San Diego, CA, USA) and R
v3.4.1. Non-parametric statistical tests were used
(Mann-Whitney U and Kruskal-Wallis for comparison
of 2 or > 2 groups, respectively, Spearman r for correla-
tions) unless specified otherwise. Univariate linear and
logistic regression models were used. Multivariable
models all included age, gender and ethnicity plus add-
itional relevant variables as described.
Results
ISG expression in patients with SARDs
We recruited a total of 164 patients with a median
(IQR) age of 48.5 (36.8, 57.3) years and disease duration
of 7.11 (3.16, 15.8) years (Table 1). The majority (122/
163, 74.8%) of patients were Caucasian reflecting a clin-
ical population in North West England and 155 (94.5%)
were female. The most prevalent conditions in our co-
hort were SLE (67 patients, 40.9%) and UCTD (43 pa-
tients, 26.2%) (Table 1).
In the whole cohort the median (IQR) ISG score was
0.8115 (0.3155, 7.052). The log-transformed ISG score
had a bimodal distribution (Fig. 1a). Using an ISG score
cut-off of > 2.466 [11], 63 (38.4%) patients had a positive
score. A finite mixture model was also used to group pa-
tients into IFN-high and IFN-low on the basis of the bi-
modal distribution and compared directly to our pre-
validated cut-off. Using this approach, all IFN-low pa-
tients were classified as ISG score negative. Conversely,
9 patients were classified as IFN-high, but ISG score
negative (see Additional file 1: Table S2).
In a subset of 92 patients, the IFNα plasma protein
level was also measured using Simoa as previously de-
scribed [14]. The median (IQR) IFNα protein concentra-
tion was 3.178 (0.361, 26.3) fg/ml. Using a cut-off of 10
fg/ml [9], 38/93 (40.9%) patients had a positive score.
There was an excellent correlation between IFNα pro-
tein levels and the 6 gene RT-qPCR ISG score (0.8307,
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Table 1 Demographic characteristics of the patient population
Whole cohort (n = 164) ISG negative (n = 101) ISG positive (n = 63) p value (ISG positive vs. negative)
Age (years) 48.5 (36.8, 57.3) 50.3 (40.6, 59.5) 44.8 (31.6, 52.8) 0.012
Gender, female 155 (94.5) 97 (96.0) 58 (92.1) 0.277
Disease duration (years) n = 158 7.11 (3.16, 15.8) 6.84 (3.06, 15.3) 8.08 (3.56, 16.1) 0.538
Age at disease onset (years) 36.5 (26.2, 47.4) 40.5 (30.1, 48.4) 31.6 (23.6, 41.1) 0.005
Ethnicity
Caucasian 122 (74.8) 80 (79.2) 42 (66.7) 0.430
Mixed 1 (0.6) 1 (0.99) 0
Asian or Asian British 8 (4.9) 3 (2.97) 5 (7.94)
Black or Black British 24 (14.6) 12 (11.9) 12 (19.0)
Other 10 (6.1) 4 (3.96) 4 (6.35)
Unknown 1 1 (0.99) 0
Disease group
UCTD 43 (26.2) 34 (33.7) 9 (14.3) < 0.0001
SLE 67 (40.9) 40 (39.6) 27 (42.9)
MCTD 13 (7.93) 4 (3.96) 9 (14.3)
SS 20 (12.2) 6 (5.94) 14 (22.2)
IIM 8 (4.88) 6 (5.94) 2 (3.17)
SSc 13 (7.93) 11 (10.9) 2 (3.17)
Concomitant medication use
Oral prednisolone 45 (27.3) 28 (27.7) 17 (27.0) 0.918
Anti-malarial* 96 (58.5) 64 (63.4) 32 (50.8) 0.112
Immunosuppressant** 47 (28.7) 28 (27.7) 19 (30.2) 0.737
Biological agent (within 6 months) 2 (1.22) 2 (1.98) 0 0.261
Daily dose prednisolone (mg) 7.5 (5.0, 10) 7.5 (5.0, 10) 7.5 (6.25, 10) 0.552
Autoantibodies
dsDNA 46 (28.0) 24 (23.8) 22 (34.9) 0.122
Ro/SS-A 49 (29.9) 18 (17.8) 31 (49.2) < 0.0001
La/SS-B 23 (14.0) 9 (8.91) 14 (22.2) 0.017
Smith 23 (14.0) 5 (4.95) 18 (28.6) < 0.0001
RNP 39 (23.8) 13 (12.9) 26 (41.3) < 0.0001
Chromatin 33 (20.1) 9 (8.91) 24 (38.1) < 0.0001
Rheumatoid factor 37 (22.6) 12 (11.9) 25 (29.7) < 0.0001
CCP 7 (4.3) 3 (2.97) 4 (6.35) 0.298
SSC-specific† 15 (9.1) 11 (10.9) 4 (6.35) 0.326
Jo-1 4 (2.4) 3 (2.97) 1 (1.59) 0.577
Clinical features
Photosensitivity 64 (39.3) 43 (42.6) 21/62 (33.9) 0.174
Myositis-specific rash 10 (6.10) 7 (6.93) 3 (4.76) 0.419
Discoid lesion 6 (3.68) 3 (2.97) 3/62 (4.84) 0.414
Mucosal ulcers 63 (38.7) 41 (40.6) 22/62 (35.5) 0.315
Raynaud’s syndrome 87 (53.4) 55 (54.5) 32/62 (51.6) 0.424
Inflammatory arthritis 75 (46.0) 42/100 (42.0) 33 (52.4) 0.129
Renal disease‡ 24 (14.9) 13/99 (13.1) 11/62 (17.7) 0.281
Neurological disease ‡ 4 (2.44) 2 (1.98) 2 (3.17) 0.498
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p < 0.0001). The 30 gene NanoString panel was mea-
sured in a subgroup of 30 patients, and there were excel-
lent correlations between NanoString and the 6-gene
RT-qPCR score (r = 0.9226, p < 0.0001) and between
NanoString and IFNα protein (r = 0.7807, p < 0.0001)
(Fig. 1b).
The number of patients with a positive ISG score var-
ied between disease groups (Fisher’s exact test p < 0.001)
(Fig. 2a and Table 1). Patients with SS and MCTD were
most likely to have a positive ISG score (14/20, [70%]
and 9/13 [69.2%], respectively) whilst positive ISG scores
were less frequent in patients with SSc and UCTD (2/13
[15.4%] and 9/43 [20.9%], respectively). The distribution
of ISG scores was similar when the relevant classification
criteria were applied in lieu of the physician diagnosis
(see Additional file 1: Figure S1).
In univariate logistic regression models, ISG score
positivity was significantly associated with MCTD (OR
[95% CI] 8.50 [2.12, 34.0]), SLE (2.55 [1.06, 6.16]) and SS
(8.81 [2.64, 29.4]). In a multivariable model which also
included medication (concomitant use (Y/N) of steroids,
immunosuppressants and anti-malarials), these signifi-
cant associations remained. We also noted an inverse as-
sociation with age (0.97, [0.94, 0.998]), Caucasian
ethnicity (0.38 [0.16, 0.91]) and anti-malarial use (0.41
[0.16, 1.04]).
Higher ISG expression is associated with haematological
abnormalities in SARDs
In the whole cohort, we found a higher frequency of
haematological abnormalities, as defined by the 1997
Modified ACR Classification Criteria for SLE [15] in pa-
tients with a positive ISG score (39/61 [63.9]% vs. 35/99
[35.4]%, p < 0.0001). In addition, patients with a positive
ISG score demonstrated lower haemoglobin concentra-
tion and lower total white cell count (WCC), lymphocyte
and neutrophil counts (Table 2). The platelet count was
also slightly lower in ISG score-positive patients, al-
though this was not statistically significant. There was
no association between ISG score positivity and other
common SARD clinical features.
In multivariable linear regression models which also in-
cluded disease group, number of autoantibodies and
medication use, the total WCC, lymphocyte count and
neutrophil count all remained significantly inversely asso-
ciated with the ISG score (see Additional file 1: Table S3).
Autoantibodies against RNA proteins are associated with
a positive ISG score
The association between the autoantibody profiles of pa-
tients was determined using logistic regression models.
In unadjusted univariate models, the odds of being in
the ISG score-positive group were significantly increased
in patients with anti-Ro, anti-La, anti-Sm, anti-RNP and
anti-chromatin antibodies and rheumatoid factor
(Table 3). There were significant differences in the fre-
quency of anti-Ro, anti-La, anti-Smith, anti-RNP, anti-
chromatin, anti-dsDNA and SSc-specific antibodies be-
tween the clinical disease groups. In a fully-adjusted
model (including disease group) anti-Smith, anti-
chromatin and rheumatoid factor all remained signifi-
cantly associated with the ISG score.
Table 1 Demographic characteristics of the patient population (Continued)
Whole cohort (n = 164) ISG negative (n = 101) ISG positive (n = 63) p value (ISG positive vs. negative)
Haematological disorder‡ 74 (46.3) 35/99 (35.4) 39/61 (63.9) < 0.0001
Data are shown as the n(%) or median (IQR). ISG = interferon-stimulated gene
*Hydroxychloroquine, mepacrine or chloroquine phosphate
**Azathioprine, methotrexate, mycophenolate mofetil, ciclosporine, tacrolimus
†Anti-Scl70, anti-centromere and anti-RNA-polymerase III
‡As the per modified 1997 ACR Classification criteria for SLE
Fig. 1 Distribution of the 6-gene ISG score in the SARD cohort. a The log-transformed 6-gene ISG score shows a bimodal distribution. b The 6-
gene ISG score correlates both with measurement of IFN protein and with a more extensive 30-gene score measured using NanoString.
Spearman’s r is shown
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In patients with no specific autoantibodies (beyond
ANA), the median (IQR) ISG score was 0.407 (0.303,
0.998) and there was a significant increase in ISG score as
the total number of autoantibodies in each patient (de-
fined as anti-dsDNA, anti-Smith, anti-RNP, anti-Ro, anti-
La, anti-CCP, anti-chromatin/nucleosome or SSc-specific
antibodies [anti-centromere, anti-Scl-70 or RNA polymer-
ase III]) increased (Kruskal-Wallis, p = 0.0001) (Fig. 2b). In
a multivariable model including disease group and medi-
cation use, each additional autoantibody increased the
odd of having a positive ISG score by over 2-fold (un-
adjusted OR 2.44 [176, 3.36], adjusted OR 2.14 [1.49,
30.5]). The association between autoantibody number and
ISG score was also determined for SLE patients alone
compared to the rest of the SARD cohort. In both cases, a
significant association was observed (OR 1.87 [1.18, 2.96]
and OR 4.62 [2.35, 90.6] respectively, Fig. 2c).
ISG score-positive patients also had a higher median
(IQR) ESR (erythrocyte sedimentation rate) (14.0 [8,
35.5] vs. 8.0 [5, 17.5] mm/h, p = 0.007) but not CRP
(serum C-reactive protein) concentration (2.0 [1.0, 4.0]
vs. 1.5 [1.0, 5.0] mg/dl, p = 0.7196). There was no associ-
ation between a positive ISG score and history of low C3
or low C4 complement.
Whole blood RNA-Seq analysis
An exploratory RNA-Seq analysis was performed on
samples from 12 SLE participants from 4 ‘cohorts’: 3
ISG positive/anti-Sm positive; 3 ISG positive/anti-Sm
negative; 3 ISG-negative/anti-Sm-positive participants
and 3 ISG-negative/anti-Sm-negative. One ISG-
negative/anti-Sm-positive patient failed QC and was
removed from the analysis. Anti-Sm was selected as it
was most strongly related to the ISG score, allowing
analysis of patients who were both ISG and Sm posi-
tive (‘double positive’), and patients with anti-Sm
without a positive ISG. Hierarchical clustering of all
coding transcripts was conducted (after removal of
any globin/HLA genes). This demonstrated some
similarities between patients belonging to the
Fig. 2 The ISG score is increased in a subset of SARD patients. a The number of patients with a positive ISG score varies between disease groups.
Each data point represents a single subject according to their clinical diagnosis. The horizontal line shows the 95th centile for healthy subjects
(ISG score of 2.466). b The ISG score is increased in patients with a greater number of autoantibodies. The total number of autoantibodies
(excluding ANA) detected in each patient is shown. Comparisons are made against patients with specific autoantibodies (Dunn’s multiple
comparison’s test), **p < 0.01, ****p < 0.0001. c The graph shows the predicted probabilities of a positive ISG score according to whether the
patients have SLE (blue) or another SARD (red). These were obtained using logistic regression models adjusted for age, gender, ethnicity and
concomitant mediation. The points and error bars show the mean and standard deviation of predicted probabilities
Table 2 Association between ISG score and haematological parameters
ISG negative (n = 101) ISG positive (n = 63) p value
Haemolytic anaemia 1/99 (1.01) 1/60 (1.67) 0.614
Haemoglobin (mg/dl) 13.4 (12.5, 13.9) 12.9 (11.6, 13.3) 0.004
Total WCC (109/l) 5.80 (4.55, 7.25) 4.95 (3.60, 5.80) 0.001
Lymphocyte count (109/l) 1.62 (1.27, 2.10) 1.31 (0.96, 1.75) 0.002
Neutrophil count (109/l) 3.39 (2.47, 4.51) 2.81 (1.99, 3.86) 0.020
Platelet count (109/l) 253 (221, 311) 249 (191, 286) 0.078
Results are presented as the n(%) or median (IQR) as appropriate. Comparisons between groups were made using the Mann-Whitney U test (continuous variables)
or Fisher’s exact test (categorical variables)
ISG = interferon-stimulated gene, WCC = white cell count
†As per the ACR SLE Classification criteria
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groupings described (Fig. 3a). Strikingly, of the 100
genes showing the greatest variance across all 11
samples, only a small number were ISGs. In addition,
although the 3 ISG positive/anti-Sm positive patients
shared high expression of the ISGs, 1 of the 3
patients (lane 1) showed markedly different expression
levels of the other genes.
Gene ontology analysis of over-represented canonical
biological pathways, between the ISG positive (n = 6)
and negative (n = 5) participants, identified differential
Table 3 Association between autoantibodies and ISG score using logistic regression models
Odds ratio (95% CI)
Univariate model Adjusted for age and gender Adjusted model 1† Adjusted model 2†
dsDNA 1.72 (0.862, 3.44) 1.45 (0.71, 2.97) 1.33 (0.576, 3.08) 1.47 (0.575, 3.74)
Ro (SS-A) 4.47 (2.20, 9.08)* 4.65 (2.24, 9.67)* 3.38 (1.37, 8.35)* 3.56 (1.32, 9.61)*
La (SS-B) 2.92 (1.18, 7.22)* 2.79 (1.11, 7.02)* 1.98 (0.602, 6.54) 2.50 (0.674, 9.26)
Smith 7.68 (2.68, 22.0)* 6.51 (2.23, 19.0)* 5.36 (1.61 17.8)* 8.35 (2.11, 32.7)*
RNP 4.76 (2.21, 10.2)* 4.07 (1.81, 9.14)* 4.11 (1.61, 10.5)* 4.08 (1.45, 11.5)*
Chromatin/nucleosome 6.29 (2.68, 14.8)* 5.57 (2.24, 13.9)* 5.13 (1.84, 14.3)* 8.09 (2.31, 28.4)*
Rheumatoid factor 4.88 (2.22, 10.7)* 5.53 (2.42, 12.6)* 7.77 (2.76, 21.9)* 7.26 (2.32, 22.7)*
Anti-CCP 2.31 (0.597, 8.91) 2.25 (0.577, 8.77) 1.46 (0.263, 8.07) 1.87 (0.272, 12.6)
SSc-specific ‡ 0.835 (0.582, 1.20) 0.862 (0.592, 1.25) 1.00 (0.614, 1.64) 1.98 (0.237, 16.5)
*p < 0.05
ISG = interferon-stimulated gene
†Model 1: adjusted for age, gender, ethnicity and clinical diagnosis
Model 2: adjusted for above plus disease duration, anti-malarial, prednisolone and immunosuppressant use
‡Anti-Scl70, anti-centromere and anti-RNA-polymerase III
Fig. 3 Whole blood transcriptome analysis of ISG-positive and ISG-negative SLE patients. a Heatmap of the 100 genes with the greatest variance.
Upregulated genes are shown in red; downregulated genes are shown in blue. The patient samples are hierarchically clustered (Euclidean
distance) over all coding genes. The heatmap is annotated to show known ISGs (dark green). Each patient sample is annotated according to the
ISG score (positive or negative) and the anti-Sm antibody status (positive or negative). b Gene ontology analysis showing the canonical pathways
that are over-represented in the ISG score-positive patients compared to the negative patients. c The expression of nucleic acid receptors (NARs)
within the RNA-Seq dataset between the ISG score-positive (n = 6) and ISG score-negative (n = 5) patients
Reynolds et al. Arthritis Research & Therapy          (2019) 21:147 Page 7 of 12
expression of nucleic acid receptors (NARs). The GO
terms with the greatest enrichment were (i) interferon
signalling, (ii) activation of IRF by cytosolic pattern rec-
ognition receptors and (iii) role of pattern recognition
receptors in recognition of bacteria and viruses (Fig. 3b).
The expression of a number of NARs was increased in
ISG score-positive patients, and a group of these were
then taken forward for further study (Fig. 3c).
Expression of nucleic acid receptors (NARs) differs
between disease groups and is associated with the ISG
score
The expression of 6 NARs (TLR3, TLR7, TLR9, DDX58
[RIG-I], MB21D1 [c-GAS] and TMEM173 [STING])
was measured in 155 patients and 16 HC (healthy con-
trols were 14/16 [87.5]% female with a median age of 42
years). Expression of all NARs (with the exception of
TLR3) was increased in SARDs compared to HC
(Fig. 4a). There was a strong correlation between the
ISG score and DDX58 expression (r = 0.7386, p < 0.0001)
and modest correlations between the ISG score and
TLR7 and MB21D1 (r = 0.3262, p < 0.0001 and r =
0.2266, p = 0.005, respectively) (Fig. 4b). Using logistic
regression DDX58 and TLR7 were associated with a
positive ISG score (OR 3.23 [2.25, 4.67] and 1.68 [1.14,
2.46] with DDX58 remaining significant in a multivari-
able model containing disease group (OR 3.69, [2.32,
5.85])).
Expression of all of the NARs (except TLR3) was
higher in patients compared to healthy controls accord-
ing to disease phenotype (see Additional file 1: Figure
S2). In linear regression models of log-adjusted NAR ex-
pression, patients with anti-Ro, anti-RNP, anti-Smith and
anti-chromatin antibodies had significantly increased
DDX58 expression (see Additional file 1: Table S4).
These associations remained significant after adjustment
for age and gender, but were no longer significant when
the ISG score was included in the model (data not
shown). Patients with anti-Ro antibodies also had signifi-
cantly lower expression of TLR9 and MB21D1 which
remained significant in a multivariable model that in-
cluded ISG score (β − 0.173 [− 0.233, − 0.015] and −
0.190 [− 0.346, − 0.034].
In an exploratory analysis, we identified clusters of pa-
tients based on the expression of the 6 NARs (Fig. 4c).
Of those patients with a positive ISG score and in-
creased DDX58 expression, a subgroup also had in-
creased expression of TLR3. In contrast, patients with
Fig. 4 Nucleic acid receptors are differentially expressed in patients with SARDs. a CTD patients have increased expression of all of the NARs
except TLR3. Comparisons were made using Dunn’s multiple comparison’s test. *p < 0.05, ***p < 0.001, ****p < 0.0001. RQ = relative quantification
of gene expression. b Heatmap showing the relative expression of each of the 6 NARs. Each row represents a single patient and is K-means
clustered into 6 groups. The rows are annotated by diagnostic group and by ISG score (ISG score-positive patients in green). c Correlation
between the NAR expression and ISG score in the combined CTD cohort. The graphs show the Spearman r for each NAR
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increased TMEM173 also had increased expression of
either TLR7 or TLR9, but not both.
TLR3, TLR9 and MB21D1 (c-GAS) expression are
independently associated with neutrophil counts
Significant correlations between a number of the NARs
and haematological parameters (haemoglobin, lympho-
cyte count, neutrophil count and platelets) were identi-
fied (Fig. 5). Interestingly, both positive and negative
correlations were observed for neutrophils. Linear re-
gression models identified that TLR3 was negatively as-
sociated, whilst TLR9 and MB21D1 were positively
associated, with neutrophil counts even after adjusted
for prednisolone use and the ISG score (Table 4).
Discussion
In this mixed SARD cohort, we used multiple meth-
odologies to identify subgroups of patients with
shared immunopathological phenotypes despite differ-
ent clinical disease manifestations. Interestingly, in
our multivariable regression models, type I IFN path-
way activity was more strongly associated with spe-
cific autoantibodies and haematological parameters
than clinical disease subtypes or individual clinical
features.
Since type I interferon was first reported to be present
in the serum of SLE patients in 1975 [16], a number of
studies have examined type I IFN expression in patients
with SARDs [17]. A panel of downstream ISGs, termed
the ‘interferon signature’, is commonly used as a surro-
gate of IFNα expression. In this study, we used our
established 6-probe RT-qPCR ISG assay [11] which has
been extensively validated in patients with monogenic
interferonopathies [18]. Although our patient and
healthy control groups varied in terms of age, we have
previously reported that our ISG score is not associated
with age [11]. We also employed NanoString technology
assessing 30 probes of interest. The significant correl-
ation between these measures demonstrates that either
method may be used to assess ISGs, with NanoString
potentially offering a less operator-dependent technique,
and thus greater potential for widespread clinical use.
We also demonstrated a strong correlation with IFNα
protein using a high-sensitivity digital ELISA, which
could detect IFNα protein in the fg/ml range. This gives
confidence that our six-gene panel is measuring the
downstream effects of in vivo IFNα activity. In 6 (6.5%)
patients, we observed a difference between the ISG score
and digital ELISA and these patients are the subject of
further study. Similarly to El-Sherbiny et al. [19], we also
observed that the ISG score has a clear bimodal distribu-
tion. Although we utilised our pre-defined threshold for
the ISG score, this approach and the results of the finite
mixture model were highly concordant.
Fig. 5 Correlation between the ISG score, NARs and haematological parameters. The figure shows a Spearman correlation matrix for the ISG
score, NAR expression and haematological parameters. Only statistically significant (p < 0.05) parameters are shown. The size of the dot represents
the strength of correlation (Spearman’s r); blue = positive correlation, red = negative correlation. Hb = haemoglobin
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In our cohort, increased IFN expression was identified
in 38% of patients, with a subpopulation in each clinical
disease group demonstrating elevated levels. The overall
number of ISG score-positive patients is lower than that
observed in other autoimmune populations, perhaps
reflecting the fact that we report an established mixed
SARD cohort (including patients with UCTD), or that
the patients had clinically stable disease, and that our
cohort was predominantly Caucasian. We confirmed the
findings of others that ISG score-positive patients were
younger, but that there was no association with disease
duration [10]. In a large study by Weckerle et al., IFNα
activity was significantly increased in patients of non-
European ancestry [20]. The relationship between IFNα
and disease activity is less clear; in patients with SLE,
some groups have reported an association [21, 22] whilst
others have not [23, 24]. Most recently, a study of the
whole blood ISG signature in SLE patients showed re-
markable stability over time with no association with
changes in disease activity [25]. This suggests that the
IFN signature may be used to identify a phenotypic sub-
population of SARD patients in cross-sectional studies.
It has been proposed that increased interferon expres-
sion may pre-date the development of SARDs. In a study
by Wither et al., increased IFN expression was identified
in asymptomatic patients with a positive ANA [26]. Fur-
thermore, a positive IFN score may predict those pa-
tients who go on to develop SLE or SS. In a study of 118
patients considered to be at risk for developing a SARDs,
the IFN score was greater in those who progressed to a
SARD than those who did not [27]. We also identified
an ISG-positive subgroup in our UCTD patients with
established disease.
In our mixed SARD cohort, we observed that this type
I IFN signature was associated with haematological indi-
ces, but not with other autoimmune features. An inverse
association between lymphocyte count and IFN score
has been reported previously [19], but in our cohort, we
also found associations with neutrophils, haemoglobin
and a trend towards a lower platelet count. In the gen-
eral population, viral infections with a corresponding
IFN response are associated with lymphopenia [28].
Similarly, chronic IFNα exposure results in reduced
haemoglobin, neutrophils and lymphocytes in patients
with chronic hepatitis C, supporting a direct role for
IFNα in the haematological abnormalities observed in
our cohort [29].
The proportion of patients with haemolytic anaemia
was very small, and we only observed a trend towards
lower platelet counts; this is in contrast to patients with
monogenic type I interferonopathies in whom
thrombocytopenia is often the most common haemato-
logical manifestation [30, 31]. In addition, iatrogenic
thrombocytopenia has been reported following
interferon-β therapy [32]. The mechanism by which IFN
may result in these haematological abnormalities is yet
to be fully elucidated; however, it is likely that a number
of mechanisms are involved including increased lympho-
cyte migration to tissue and reduced egress from lymph
nodes [33].
In this larger clinical cohort, we corroborated our pre-
vious findings of a positive association between elevated
type I interferon and the RNA-associated autoantibodies
anti-Ro, anti-La, anti-Sm and anti-RNP [9]. Additionally,
we observed an association between anti-chromatin/nu-
cleosome antibodies and rheumatoid factor and a posi-
tive ISG score which appeared to be independent of the
clinical diagnosis. Importantly, anti-chromatin antibodies
were associated with increased IFNα whilst anti-dsDNA
antibodies were not, suggesting that the DNA-histone
complex may be more interferonogenic than DNA alone.
This observation is in contrast with the study by Kirou
et al. which found an association between IFNα and
anti-dsDNA titres in SLE patients, although this may
have been confounded by increased disease activity [21].
RNA-containing immune complexes appear to directly
increase IFNα production in plasmacytoid dendritic cells
(pDCs) in a mechanism that is dependent on both toll-
like receptors (TLRs) and the Fc gamma receptor IIa
[34], but may also trigger IFNα indirectly via effects on
neutrophils [35].
We observed increased expression of all of the nuclear
receptors, except TLR3, in whole blood of patients with
SARDs compared to healthy controls. This supports the
Table 4 Association between NAR expression and neutrophil count
Beta coefficient (95% CI)
Univariate model Adjusted model 1† Adjusted model 2† Adjusted model 3†
TLR3 −0.113 (−0.206, −0.019)* −0.121 (−0.212, −0.030)* − 0.116 (− 0.203, − 0.29)* −0.107 (− 0.194, − 0.022)*
TLR9 0.161 (0.072, 0.250)* 0.138 (0.048, 0.229)* 0.102 (0.011, 0.193)* 0.095 (0.006, 0.184)*
MB21D1 0.151 (0.065, 0.237)* 0.126 (0.039, 0.213)* 0.096 (0.008, 0.184)* 0.100 (0.015, 0.186)*
Linear regression models of log-normalised neutrophil counts
†Model 1: adjusted for age, gender, ethnicity (Caucasian vs non-Caucasian) and clinical diagnosis
Model 2: as above plus adjusted for prednisolone, anti-malarial and immunosuppressant use
Model 3: as above plus adjustment for ISG score
*p < 0.05
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study by Chauhan et al. which identified increased
PBMC TLR7 and TLR9 expression in SLE patients com-
pared to healthy controls [36]. However, in our cohort,
DDX58/RIG-I, MB21D1 and TLR7 expression were as-
sociated with the ISG score which may reflect our mea-
surements in whole blood which does not allow
adjustment for immune cell heterogeneity. Maria et al.
reported that TLR7 was increased and TLR9 decreased
in the pDCs and monocytes of IFN-positive SS patients
[37]. In addition, DDX58/RIG-I was also increased in
monocytes from IFN-positive patients. Similarly in child-
hood SLE, increased expression of TLR7 and a number
of RIG-like receptors (including DDX58) has been re-
ported in IFN score-positive patients [38].
Unsupervised hierarchical clustering of NAR expres-
sion identified groups of ISG-score-negative patients
with high TLR3 expression, or high TLR9 and/or
TMEM173/STING expression. The potential roles of
these receptors in IFN-low subgroups warrant further
investigation. Interestingly, although TLR3 was not in-
creased in SARD patients compared to controls, there
was a significant independent negative association with
neutrophil count (in opposition to MB21D1 and TLR9)
suggesting that non-IFN mechanisms might be involved.
In contrast, TLR3 ligation in mice has been demon-
strated to result in increased neutrophil numbers sug-
gesting that increased TLR expression and increased
TLR3 signalling may not explain this association [39].
Conclusions
In summary, transcriptomic and protein studies demon-
strate that for subpopulations of the SARDs there are
overlapping IFN-related biomarkers which may repre-
sent shared molecular drivers of disease and are more
associated with specific disease features and ENA than
clinical diagnoses. We also noted that NAR expression
differs between ISG-positive and ISG-negative patients
which may point to different immunopathological mech-
anisms between ISG “immunophenotypes”. Our observa-
tions suggest that the molecular taxonomy of a mixed
SARD cohort is inconsistent with the clinical phenotype.
A targeted approach to treatment of patients with a
shared immunopathogenesis may therefore offer advan-
tages over the current classification of disease.
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